Compare Summit Therapeutics Inc (SMMT) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Under Armour Inc Class A — how do they compare? Summit Therapeutics Inc trades at $17.59 (market cap $13.71B), while Under Armour Inc Class A trades at $4.78 (market cap $2.07B). The key difference: Summit Therapeutics Inc is far larger — about 6.6× Under Armour Inc Class A's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Under Armour Inc Class A for 18 Days on average.
| SMMT | UA | |
|---|---|---|
Market Cap | $13.71B | $2.07B |
Volume | 6,173,057 | 2,680,141 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.38 | $7.88 |
52-Week Low | $12.43 | $3.96 |
Typical Hold Time | 16 Days | 18 Days |
Enterprise Value | $13.04B | $3.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
Under Armour (UA) trades at $4.74, up 0.85% with a bullish technical signal despite mixed earnings. The company faces revenue declines and negative profitability with a -9.99% net margin, though valuation metrics like P/S of 0.41 appear attractive. Recent Q2 2026 earnings beat expectations, but guidance has been lowered amid softer consumer demand.
Outlook remains challenging with significant cash burn and competitive pressures. While analyst sentiment is mixed with 39.7% buy ratings, the stock offers speculative value for turnaround investors willing to bear execution risks and ongoing revenue headwinds in the athletic apparel sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
